2025-12-16T11:43:51Z
2025-12-16T11:43:51Z
2024-01-16
2025-12-05T11:33:51Z
Lung-resident mesenchymal stem cells (LR-MSC) are thought to participate in idiopathic pulmonary fibrosis (IPF) by differentiating into myofibroblasts. On the other hand, LR-MSC in IPF patients present senescence-related features. It is unclear how they respond to a profibrotic environment. Here, we investigated the profibrotic response of LR-MSC isolated from IPF and control (CON) patients. LR-MSC were inoculated in mice 48 h after bleomycin (BLM) instillation to analyze their contribution to lung damage. In vitro, LR-MSC were exposed to TGF beta. Mice inoculated with IPF LR-MSC exhibited worse maintenance of their body weight. The instillation of either IPF or CON LR-MSC sustained BLM-induced histological lung damage, bronchoalveolar lavage fluid cell count, and the expression of the myofibroblast marker, extracellular matrix (ECM) proteins, and proinflammatory cytokines in the lungs. In vitro, IPF LR-MSC displayed higher basal protein levels of aSMA and fibronectin than CON LR-MSC. However, the TGF beta response in the expression of TGF beta, aSMA, and ECM genes was attenuated in IPF LR-MSC. In conclusion, IPF LR-MSC have acquired myofibroblastic features, but their capacity to further respond to profibrotic stimuli seems to be attenuated. In an advanced stage of the disease, LR-MSC may participate in disease progression owing to their limited ability to repair epithelial damage.
Article
Published version
English
Fibrosi pulmonar; Malalties pulmonars obstructives cròniques; Farmacologia respiratòria; Pulmonary fibrosis; Chronic obstructive pulmonary diseases; Pulmonary pharmacology
MDPI AG
Reproducció del document publicat a: https://doi.org/10.3390/cells13020160
Cells, 2024, vol. 13, num. 2, 160
https://doi.org/10.3390/cells13020160
cc-by (c) Escarrer Garau, Gabriel et al., 2024
https://creativecommons.org/licenses/by/4.0/